Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard H Feldman

Showing results (71-80 of 161) with videos related to

Pageof 17
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|January 12, 2026
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's diseasePhilip Scheltens, Alireza Atri, Howard H Feldman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsPaul W H Brewster, Diane M Jacobs, Nicole D Anderson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 10, 2024
Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspectiveKhushbu J Patel, David Yang, Howard H Feldman, et al.
Ebiomedicine|December 15, 2023
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trialNicholas C Cullen, Petr Novak, Duygu Tosun, et al.
Journal of the American Heart Association|January 19, 2026
Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 ConferenceThalia S Field, Sarah U Morton, Marie Brossard-Racine, et al.
Lancet (London, England)|March 22, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsJeffrey L Cummings, Alireza Atri, Mary Sano, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
A novel PS1 gene mutation in a large Aboriginal kindredRachel Butler, B Lynn Beattie, Umamon Puang Thong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 10, 2018
Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trialMary Sano, Susan Egelko, Carolyn W Zhu, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 12, 2007
Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individualsKevin R Peters, Kenneth Rockwood, Sandra E Black, et al.
Brain : a Journal of Neurology|October 31, 2006
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin geneIan R A Mackenzie, Matt Baker, Stuart Pickering-Brown, et al.
Pageof 17

Showing results (71-80 of 161) with videos related to

Sort By:
Pageof 17
Alzheimer'S & Dementia (New York, N. Y.)|January 12, 2026
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's diseasePhilip Scheltens, Alireza Atri, Howard H Feldman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsPaul W H Brewster, Diane M Jacobs, Nicole D Anderson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 10, 2024
Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspectiveKhushbu J Patel, David Yang, Howard H Feldman, et al.
Ebiomedicine|December 15, 2023
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trialNicholas C Cullen, Petr Novak, Duygu Tosun, et al.
Journal of the American Heart Association|January 19, 2026
Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 ConferenceThalia S Field, Sarah U Morton, Marie Brossard-Racine, et al.
Lancet (London, England)|March 22, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsJeffrey L Cummings, Alireza Atri, Mary Sano, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
A novel PS1 gene mutation in a large Aboriginal kindredRachel Butler, B Lynn Beattie, Umamon Puang Thong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 10, 2018
Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trialMary Sano, Susan Egelko, Carolyn W Zhu, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 12, 2007
Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individualsKevin R Peters, Kenneth Rockwood, Sandra E Black, et al.
Brain : a Journal of Neurology|October 31, 2006
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin geneIan R A Mackenzie, Matt Baker, Stuart Pickering-Brown, et al.
Pageof 17